Wei Hou
Wei Hou has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Yujun Song
Center for Modern Physics Technology, School of Mathematics and Physics, University of Science and Technology Beijing, Beijing 100083, China
3 shared publications Shangqing Jing
2 shared publicationsWenqi Song
2 shared publications- Alexandr V. Sadovnikov
Saratov State University
1 shared publication - Maria V. Lomova
Saratov State University
1 shared publication Rui Xue Zhang
Precision Regenerative Medicine Research Centre, Medicine-School of Pharmacy, Macau University of Science and Technology, Macau Coloane Shek Pai Wan Road, Qingtian Hui, Macau 999078, China
1 shared publication
Latest Publications
- 11 March 2026
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 12 (4) , 1968-1990
Nanomedicine-Mediated Immunotherapy for Cancer Treatment
Since the dawn of the 21st century, the convergence of interdisciplinary fields─including life sciences, nanotechnology, and information technology─propels pharmaceuticals and healthcare into a period of rapid transformation. This paradigm shift catalyzes the emergence of innovative medical technologies. Immuno-oncology plays a pivotal role in cancer therapeutics. However, most patients derive limited benefits from currently available immunotherapies, while many experience immune-related adverse events (irAEs). Consequently, significant research efforts focus on developing nanomedicines that attenuate immunosuppression within the tumor microenvironment (TME) or enhance immune-cell-mediated tumor recognition and cytotoxicity. This review outlines nanomedicine-mediated immunotherapeutic strategies against tumors. Such novel approaches function as monotherapies or synergize with conventional oncology treatments to achieve superior therapeutic outcomes. Nanomedicine offers a transformative framework for precision cancer therapy through rational design principles that integrate tumor-specific characteristics and in vivo kinetics of drug transport. These advances hold promise for augmenting existing treatments and expanding therapeutic options for cancer patients. Finally, we critically analyze current challenges and depict the future directions in nanomedicine-driven immunotherapy, aiming to harness the immune system effectively against malignancies and ultimately expand the oncologist’s armamentarium.
- 11 March 2026
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 12 (4) , 1968-1990
Nanomedicine-Mediated Immunotherapy for Cancer Treatment
Since the dawn of the 21st century, the convergence of interdisciplinary fields─including life sciences, nanotechnology, and information technology─propels pharmaceuticals and healthcare into a period of rapid transformation. This paradigm shift catalyzes the emergence of innovative medical technologies. Immuno-oncology plays a pivotal role in cancer therapeutics. However, most patients derive limited benefits from currently available immunotherapies, while many experience immune-related adverse events (irAEs). Consequently, significant research efforts focus on developing nanomedicines that attenuate immunosuppression within the tumor microenvironment (TME) or enhance immune-cell-mediated tumor recognition and cytotoxicity. This review outlines nanomedicine-mediated immunotherapeutic strategies against tumors. Such novel approaches function as monotherapies or synergize with conventional oncology treatments to achieve superior therapeutic outcomes. Nanomedicine offers a transformative framework for precision cancer therapy through rational design principles that integrate tumor-specific characteristics and in vivo kinetics of drug transport. These advances hold promise for augmenting existing treatments and expanding therapeutic options for cancer patients. Finally, we critically analyze current challenges and depict the future directions in nanomedicine-driven immunotherapy, aiming to harness the immune system effectively against malignancies and ultimately expand the oncologist’s armamentarium.
- 20 July 2025
- Published by American Chemical Society (ACS) in Langmuir
Gold-Enhanced Lanthanide Nanomedicine for Near-Infrared Photodynamic Therapy
Cancer remains a major global health challenge due to its high morbidity and mortality rates. Traditional treatments, such as surgery, radiotherapy, and chemotherapy, have some clear limitations, which is why there is a growing need for innovative therapeutic modalities. One precise targeting of tumors with few side effects can be achieved through a promising modality called photodynamic therapy (PDT). PDT is a noninvasive cancer treatment that uses photosensitizers to produce cytotoxic species that selectively kill cancer cells under light exposure. In recent years, a variety of nanoparticles (NPs) have been developed. Among them, gold-doped lanthanide NPs (Au-Ln NPs) stand out as a significant advancement in PDT due to the integration of the surface plasmon resonance (LSPR) properties of AuNPs and upconversion (UC) luminescence of Ln NPs. In this perspective, we review various synthesis methods for upconversion nanoparticles (UCNPs) and gold nanoparticles (AuNPs), highlighting their integration into multifunctional Au-Ln NPs for enhanced PDT. By using near-infrared (NIR) light, Au-Ln UCNPs can penetrate deep into tissues, making them particularly effective for treating deeply seated tumors. However, the synthesis of Au-Ln NPs comes with its own challenges. The main challenges include the uniform distribution of gold doping, the control of the particle size and shape, and the reproducibility as well as scalability. Overcoming these challenges for controlled synthesis and enhanced PDT will be critical. Correspondingly, their PDT applications are discussed in vitro and in vivo. Lastly, the current challenges, limitations, and future prospects will be explored.
- 20 July 2025
- Published by American Chemical Society (ACS) in Langmuir
Gold-Enhanced Lanthanide Nanomedicine for Near-Infrared Photodynamic Therapy
Cancer remains a major global health challenge due to its high morbidity and mortality rates. Traditional treatments, such as surgery, radiotherapy, and chemotherapy, have some clear limitations, which is why there is a growing need for innovative therapeutic modalities. One precise targeting of tumors with few side effects can be achieved through a promising modality called photodynamic therapy (PDT). PDT is a noninvasive cancer treatment that uses photosensitizers to produce cytotoxic species that selectively kill cancer cells under light exposure. In recent years, a variety of nanoparticles (NPs) have been developed. Among them, gold-doped lanthanide NPs (Au-Ln NPs) stand out as a significant advancement in PDT due to the integration of the surface plasmon resonance (LSPR) properties of AuNPs and upconversion (UC) luminescence of Ln NPs. In this perspective, we review various synthesis methods for upconversion nanoparticles (UCNPs) and gold nanoparticles (AuNPs), highlighting their integration into multifunctional Au-Ln NPs for enhanced PDT. By using near-infrared (NIR) light, Au-Ln UCNPs can penetrate deep into tissues, making them particularly effective for treating deeply seated tumors. However, the synthesis of Au-Ln NPs comes with its own challenges. The main challenges include the uniform distribution of gold doping, the control of the particle size and shape, and the reproducibility as well as scalability. Overcoming these challenges for controlled synthesis and enhanced PDT will be critical. Correspondingly, their PDT applications are discussed in vitro and in vivo. Lastly, the current challenges, limitations, and future prospects will be explored.